Discussion  by unknown
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 5 Smolock et al 127512. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG; TASC II Working Group. Inter-Society Consensus for the
Management of Peripheral Arterial Disease (TASC II). J Vasc Surg
2007;45(1 Suppl):S5-67.
13. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
et al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
14. Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ,
Lumsden AB. Impact of runoff on superﬁcial femoral artery endolu-
minal interventions for rest pain and tissue loss. J Vasc Surg 2008;48:
619-25.
15. Bakken AM, ProtackCD, SaadWEA, Rhodes JR,Hart JP,WaldmanDL,
et al. Impact of chronic kidney disease on outcomes of superﬁcial femoral
artery endoluminal interventions. Ann Vasc Surg 2009;23:560-8.
16. Smolock CJ, Anaya-Ayala JE, El-Sayed HF, Naoum JJ, Lumsden AB,
Davies MG. Clinical efﬁcacy of concomitant tibial interventionsassociated with superﬁcial femoral artery interventions in critical limb
ischemia. J Vasc Surg 2013;57:19-27.
17. Kashyap VS, Gilani R, Bena JF, Bannazadeh M, Sarac TP. Endovas-
cular therapy for acute limb ischemia. J Vasc Surg 2011;53:340-6.
18. Baril DT, Chaer RA, Rhee RY, Makaroun MS, Marone LK. Endo-
vascular interventions for TASC II D femoropopliteal lesions. J Vasc
Surg 2010;51:1406-12.
19. DeRubertis BG, Pierce M, Chaer RA, Rhee SJ, Benjeloun R, Ryer EJ,
et al. Lesion severity and treatment complexity are associated with
outcome after percutaneous infra-inguinal intervention. J Vasc Surg
2007;46:709-16.
Submitted Jul 17, 2012; accepted Feb 26, 2013.
Additional material for this article may be found online
at www.jvascsurg.org.DISCUSSIONMichael C. Stoner (Greenville, NC). Good morning
members and guests of the Society. Today, Dr Smolock and his
colleges from Houston have presented their two-decade experi-
ence with open and endovascular revascularization for complex
femoro-popliteal arterial occlusive disease. By the numbers, these
data are impressive, and represent over 2500 interventions for
severe claudication, rest pain, and tissue loss. The authors are to
be lauded for the 20-year study time frame, thus presenting us
with an evolving endovascular experience that mimics the national
transition to an endovascular-weighted stance towards lower
extremity arterial disease. In brief, the data, which likely represent
the practice pattern for many in this room, showed that patients
with systemic illness such diabetes or metabolic syndrome were
more likely to have percutaneous therapy, and bypass was more
commonly employed in TASC II D cases. While the surgeon-
centric outcome of primary assisted patency was similar in the
two groups, patient-centric outcomes involving limb salvage and
the novel “clinical efﬁcacy” favored patients undergoing bypass.
However, the data as presented are difﬁcult to draw meaningful
conclusions from. A few questions I have for the authors:
1. The most glaring issue, which was appropriately acknowl-
edged in the manuscript, is the selection bias. A large
well-sized longitudinal database such as this would most
appropriately be analyzed with a propensity score-weighted
proportional hazard model. Without such an analysis, these
data remain observational in nature, and the study fails to
reach its potential. Have you considered such an analysis
to correct for bias?
2. In your paper, there is a disconnect between assisted patency
and clinical efﬁcacy. This discordant ﬁnding highlights a major
issue in the vascular literature today. For instance, considerthe rather nebulous ﬁndings of theCLEVER trial. Do you think
that this discordance was related to the robustness or ABI
improvement following revascularization? It would be very
informative to stratify your clinical efﬁcacy endpoint by initial
ABI gain.
3. As your group gained experience with endovascular therapy,
did your selection criteria and outcomes change over time?
What about utilization of endovascular adjuncts such as stents
or atherectomy?
I’d like to speciﬁcally thank Dr Smolock for an advanced copy
of the manuscript, and the Society for the privilege of starting the
discussion.
Dr Christopher Smolock. Thank you for your questions,
Dr Stoner. We acknowledge selection bias, and we look forward
to conducting the analysis to correct for that bias in the paper.
The disconnect between the patencies and the clinical efﬁcacies
is something that has been very interesting to us, and I think it
does have to do with the patients being sicker in the endovas-
cular group: more diabetes, more metabolic syndrome, probably
worse small vessel disease even though tibial runoff scores were
better in the endovascular group. However, those runoff scores
only calculate to the ankle and do not include the foot arch or
angiosomes, thus not accounting for small vessel disease in
the foot. I believe this is probably tied together using the
ABI/TBI data. Endovascular therapy results in a lower ABI/
TBI than does open bypass. As the technology became avail-
able, the use of stents initially increased but then decreased
and leveled off as our group approach became fairly conservative
with minimal primary stenting, doing so for poor results or
dissection with angioplasty alone. We do not do very much
atherectomy.
